论文部分内容阅读
目的探讨达那唑对性早熟患儿的使用价值。方法选择13例临床已确诊为性早熟患儿,经促性腺激素释放激素激动剂(GnRHa)治疗到骨龄超过12岁后换用达那唑治疗,对达那唑治疗前后各1年的数据进行比较。结果达那唑治疗后生长速度由(4.55±2.63)cm/年增加到(6.78±3.11)cm/年。预测成年身高(PAH)由(156.79±7.30)cm增加到(158.01±6.66)cm。骨龄成熟速度(ΔBA/ΔCA)由(0.36±0.58)增加到(0.95±0.82)。身高相对应的标准差积分值无明显变化。结论达那唑药物治疗可以促进骨龄超过12岁的性早熟患儿身高生长。可以作为GnRHa停药后继续用药的选择。
Objective To investigate the use value of danazol in children with precocious puberty. Methods Thirteen patients with clinically proven precocious puberty were enrolled. After GnRHa was administered to patients with bone age over 12 years old, danazol was used for treatment. The data of each year before and after danazol treatment Compare Results The growth rate of danazol increased from 4.55 ± 2.63 cm / year to 6.78 ± 3.11 cm / year. The predicted adult height (PAH) increased from (156.79 ± 7.30) cm to (158.01 ± 6.66) cm. Bone age maturation speed (ΔBA / ΔCA) increased from (0.36 ± 0.58) to (0.95 ± 0.82). The standard deviation of height corresponds to no significant change in integral value. Conclusion Danazol drug treatment can promote the growth of children with precocious puberty over 12 years old. GnRHa can be used as GnRHa after discontinuation of choice.